Answers are grounded in this paper and cite their sources.
Molecular classification has transformed the management of brain tumors by enabling more accurate prognostication and personalized treatment. However, timely molecular diagnostic testing for brain tumor patients is limited [1–3], complicating surgical and adjuvant treatment and obstructing clinical trial enrollment [4]. Here, we developed DeepGlioma, a rapid (<90 seconds), AI-based diagnostic screening system to streamline the molecular diagnosis of diffuse gliomas. DeepGlioma is trained using a multimodal dataset that includes stimulated Raman histology (SRH), a rapid, label-free, non-consumptive, optical imaging method [5–7], and large-scale, public genomic data. In a prospective, multicenter, international testing cohort of diffuse glioma patients (N = 153) who underwent real-time SRH imaging, we demonstrate that DeepGlioma can predict the molecular alterations used by the World Health Organization (WHO) to define the adult-type diffuse glioma taxonomy (IDH mutation, 1p19q co-deletion, ATRX mutation) [8], achieving a mean molecular classification accuracy of 93.3 (±1.6)%. Our results represent how artificial intelligence and optical histology can be used to provide a rapid and scalable adjunct to wet lab methods for the molecular diagnosis of diffuse glioma patients.
No takes yet. Share an insight, caveat, or question.
Hollon et al. (2022) studied this question.